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Objectives The purpose of this study was to analyze the incidence of new atrial fibrillation or flutter (AFF) in the
EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) database.
Background Aldosterone antagonism in heart failure might influence atrial fibrosis and remodeling and, therefore, risk of de-
veloping AFF. The development of new AFF was a pre-specified secondary endpoint in the EMPHASIS-HF study.
Methods Patients in New York Heart Association functional class II and with ejection fraction 35% were eligible for
EMPHASIS-HF. History of AFF at baseline was reported by investigators using the study case report form.
New onset AFF (in those with no history of AFF at baseline) was reported using a specific endpoint form; in
a sensitivity analysis we also examined the effect of eplerenone on AFF reported as an adverse event.
Results New onset AFF was significantly reduced by eplerenone: 25 of 911 (2.7%) versus 40 of 883 (4.5%) in the pla-
cebo group (hazard ratio [HR]: 0.58, 95% confidence interval [CI]: 0.35 to 0.96; p  0.034). The reduction in the
primary endpoint with eplerenone was similar among patients with and without AFF at baseline (HR: 0.60, 95%
CI: 0.46 to 0.79 vs. HR: 0.70, 95% CI: 0.57 to 0.85, respectively; p for interaction  0.41). The risk of cardiovas-
cular (CV) death or hospital admission for worsening heart failure, the primary endpoint, was not significantly
different in subjects with and without AFF at baseline (both study groups combined: HR: 1.23, 95% CI: 0.81 to
1.86; p  0.33).
Conclusions In patients with systolic heart failure and mild symptoms, eplerenone reduced the incidence of new onset AFF. The
effects of eplerenone on the reduction of major CV events were similar in patients with and without AFF at
baseline. (J Am Coll Cardiol 2012;59:1598–603) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.063Atrial fibrillation is common in patients with chronic heart
failure (HF), and its prevalence increases with the severity of
the disease (1,2). The development of atrial fibrillation with
an ensuing decline in cardiac function may also cause
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May 1, 2012:1598–603 Eplerenone and AF in Mild Systolic Heart Failureincreased mortality. Development of atrial fibrillation is
clearly undesirable in HF, and treatments that may prevent
it are therefore conceptually attractive in HF.
The extent of activation of the renin-angiotensin-
aldosterone system also increases with the severity of HF (5)
and both angiotensin II and aldosterone may lead to atrial
fibrosis and contribute to the development of atrial fibrilla-
tion or flutter (AFF) (6,7).
Angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) have been shown to
reduce the incidence of atrial fibrillation in patients with HF
(as well as other types of cardiovascular disease) in meta-
analyses including both primary and secondary prevention
(8,9), although not all studies have confirmed this finding in
primary prevention (10,11).
Activation of mineralocorticoid receptors by aldosterone
and cortisol has deleterious effects in patients with cardio-
vascular disease (12). Treatment with mineralocorticoid
receptor antagonists (MRA) has been demonstrated to
reduce outcomes in patients with mild to severe systolic HF
(13,14) as well as after myocardial infarction (15). Aldoste-
rone has a more pro-fibrotic action than angiotensin II (12),
but whether antagonists, which block activation of the
mineralocorticoid receptor by aldosterone and other corti-
costeroids, reduce the incidence of AFF is unclear, espe-
cially in patients with systolic HF already treated with an
ACE inhibitor or ARB. A small study has suggested that
spironolactone may prevent the re-occurrence of AF in
patients with normal left ventricular systolic function (16).
We therefore prospectively examined this question in the
EMPHASIS-HF (Eplerenone in Mild Patients Hospital-
ization And SurvIval Study in Heart Failure) study. In
EMPHASIS-HF, the MRA eplerenone, or placebo, was
added to an ACE inhibitor or ARB, and a beta-blocker, in
patients with systolic HF and mild symptoms (13). We also
report the effect of eplerenone in patients with and without
AFF at baseline and the relationship between baseline AFF
and subsequent events.
Methods
The design of the trial has been published in detail (13,17).
In brief, patients were eligible if they were at least 55 years
of age, in New York Heart Association functional class II,
had an ejection fraction of no more than 30% (or, if between
30% and 35%, QRS duration had to be 130 ms), and they
were treated with the recommended or maximally tolerated
dose of ACE inhibitor (or an ARB or both) and a
beta-blocker (unless contraindicated). Randomization was
to occur within 6 months of hospitalization for a cardiovas-
cular reason or, if no such hospitalization, if plasma B-type
natriuretic peptide was at least 250 pg/ml or N-terminal
pro–B-type natriuretic peptide was at least 500 pg/ml in
men (750 pg/ml in women). Key exclusion criteria were
serum potassium 5.0 mmol/l, estimated glomerular filtra-
tion rate (eGFR) 30 ml/min/1.73 m2, need for a fotassium-sparing diuretic, and
ny other significant comorbid
ondition.
The trial was approved by each
enter’s ethics committee. All pa-
ients provided written informed
onsent.
tudy procedures. We used a
omputerized randomization sys-
em involving concealed study-
roup assignments to randomly
ssign patients to eplerenone or
atching placebo with no stratifi-
ation for subgroups. Eplerenone
r matching placebo was started
t a dose of 25 mg once daily (or
5 mg alternate days if eGFR
as 30 to 49 ml/min/1.73 m2)
nd increased after 4 weeks to 50 mg once daily (25 mg daily
f eGFR was 30 to 49 ml/min/1.73 m2), provided the serum
otassium was no more than 5.0 mmol/l. Thereafter,
nvestigators reviewed patients every 4 months and were
nstructed to decrease the dose of study drug if potassium
as 5.5 mmol/l or more and to withhold it if potassium was
.0 mmol/l or more. Potassium was to be rechecked within
2 h and study drug restarted only if potassium was 5.0
mol/l. An electrocardiogram was recorded at baseline and
t study closure.
trial fibrillation/flutter. BASELINE AFF. AFF status was
etermined from 3 separate parts of the study case report
orm (CRF): 1) the baseline electrocardiogram report; 2) the
tiology of HF report and prior index hospitalization; and
) the medical history page. Patients without AFF at
aseline had no report of AFF in any of these 3 CRF
ections. Patients with AFF at baseline had a report of AFF
n any 1 of these sections.
NEW ONSET AFF. Because new onset AFF was a pre-
pecified endpoint, a specially designed CRF focused on the
ccurrence of AFF during follow-up was collected during
he study for all patients. We also performed a sensitivity
nalysis by examining adverse events reports of AFF.
atients with new onset AFF were defined as those without
FF at baseline who had an endpoint CRF report of AFF
uring follow-up (or, in the sensitivity analysis, an adverse
vent report of AFF).
We also examined the impact of baseline AFF on
rimary and secondary outcomes and the effect of epler-
none by baseline AFF. The primary endpoint was the
rst occurrence of either death from cardiovascular causes
r hospitalization for HF. The other key secondary
ndpoints were hospitalization for HF or death from any
ause, death from any cause, death from cardiovascular
auses, hospitalization for any cause, and hospitalization
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AFF  atrial fibrillation or
flutter
ARB  angiotensin
receptor blocker
CI  confidence interval
CRF  case report form
eGFR  estimated
glomerular filtration rate
HF  heart failure
HR  hazard ratio
MRA  mineralocorticoid
receptor antagonist(s)or HF.
s and F
ceptor b
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Eplerenone and AF in Mild Systolic Heart Failure May 1, 2012:1598–603Statistical analysis. The comparability of baseline charac-
teristics between subjects without or with baseline AFF was
assessed by 2-sample t test for continuous variables and
Fisher’s exact test for categorical variables.
The unadjusted and adjusted treatment effect on the risk
of new onset AFF was assessed by Cox proportional hazards
models without or with adjusting for the following pre-
specified baseline prognostic factors in the model: age,
eGFR or serum creatinine, ejection fraction, body mass
index, hemoglobin, heart rate, systolic blood pressure, dia-
betes mellitus, history of hypertension, prior myocardial
infarction, and left bundle branch block or QRS duration
130 ms.
Additionally, the subgroup analyses of the unadjusted treat-
ment effect on the risk of primary and secondary outcomes
were conducted on all randomized patients and according to
the intention-to-treat principle stratified by subjects with or
without baseline AFF using Kaplan-Meier estimates and Cox
proportional hazards models including treatment as the only
factor. The treatment-by-baseline AFF subgroup interaction
was evaluated using a Cox proportional hazards model with
terms for treatment, baseline AFF, and interactions between
treatment and baseline AFF subgroup.
The association between baseline AFF and the risk of
primary and secondary endpoints was assessed using Cox
proportional hazards analyses including baseline AFF as the
major factor in the model. Additionally, a multivariate Cox
proportional hazards model was performed adjusting for the
list of baseline characteristics that were found to be signif-
icantly imbalanced between patients without or with base-
Baseline Characteristics in Patients With and Without AFFTable 1 Baseline Characteristics in Patients With and Without
No AFF (n  1,794)
Eplerenone
(n  911)
Placebo
(n  883)
T
(n 
Age, yrs 68 7.6 67.9 7.5 67.
Men, % 675 (74) 665 (75) 1,34
Ischemic heart failure, % 659 (72.3) 619 (70.1) 1,27
Previous hospitalization for CHF, % 451 (49.5) 433 (49.0) 88
Hypertension, % 588 (64.5) 569 (64.4) 1,15
Diabetes mellitus, % 330 (36.2) 275 (31.1) 60
Coronary artery bypass grafting, % 173 (19.0) 158 (17.9) 33
EF, % 26 (4.6) 26 (4.7) 2
Heart rate, beats/min 72.1 (14.4) 71.6 (14.6) 71
Serum creatinine, mg/dl 1.1 (0.3) 1.1 (0.3) 1
Medications, %
Diuretics 788 (86.5) 777 (88) 1,56
ACE inhibitor/ARB 876 (96.2) 840 (95.1) 1,71
Beta-blocker 820 (90.0) 801 (90.7) 1,62
Digitalis glucosides 213 (23.4) 204 (23.1) 41
Amiodarone 116 (12.7) 136 (15.4) 25
Lipid-lowering agents 654 (71.8) 630 (71.4) 1,28
Values are mean  SD or n (%). *p Values were based on 2-sample t test for continuous variable
ACE  angiotensin-converting enzyme; AFF  atrial fibrillation or flutter; ARB  angiotensin reline AFF from Table 1.Results
The study profile is presented in Figure 1 and the demo-
graphic characteristics of patients with and without AFF at
baseline are presented in Table 1. Nine hundred and
forty-three patients (34%) had AFF. Patients with AFF
differed from non-AFF patients in almost all variables.
Patients with AFF were significantly older and larger, had
more prior hospitalizations, and had more hypertension but
less diabetes. While ejection fraction was similar between
those with and without AFF, patients with AFF had a
higher heart rate and slightly higher serum creatinine. The
balanced randomization between allocation groups was
maintained despite absence of stratification for baseline AF.
New onset atrial fibrillation is presented in Figure 2,
according to treatment group. Onset of new atrial fibrilla-
AFF (n  943)
)
Eplerenone
(n  453)
Placebo
(n  490)
Total
(n  943)
p Value
(No AFF vs. AFF)
5 70.1 7.7 69.9 7.7 70.0 7.7 0.0001*
380 (84) 407 (83) 787 (83) 0.0001*
2) 292 (64.5) 316 (64.5) 608 (64.5) 0.0003*
3) 263 (58.1) 293 (59.8) 556 (59) 0.0001*
5) 322 (71.1) 340 (69.4) 662 (70.2) 0.0029*
7) 129 (28.5) 125 (25.5) 254 (26.9) 0.0003*
5) 83 (18.3) 102 (20.8) 185 (19.6) 0.4717
) 26.3 (4.7) 26.2 (4.7) 26.3 (4.7) 0.2034
5) 76.7 (17.3) 76 (16.6) 76.4 (16.9) 0.0001*
) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 0.0001*
2) 415 (91.6) 454 (92.7) 869 (92.2) 0.0001*
7) 434 (95.8) 465 (94.9) 899 (95.3) 0.6976
4) 413 (91.2) 447 (91.2) 860 (91.2) 0.4905
2) 214 (47.2) 254 (51.8) 468 (49.6) 0.0001*
0) 132 (29.1) 150 (30.6) 282 (29.9) 0.0001*
6) 266 (58.7) 295 (60.2) 561 (59.5) 0.0001*
isher’s exact test for categorical variables.
locker; bpm  beats per minute; EF  ejection fraction; CHF  chronic heart failure.
Figure 1 Study Profile
AFF  atrial fibrillation or flutter.AFF
otal
1,794
9 7.
0 (75)
8 (71.
4 (49.
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25 of 911 eplerenone-treated patients (2.7%) versus 40 of
883 patients (4.5%) in the placebo group (hazard ratio
[HR]: 0.58, 95% confidence interval [CI]: 0.35 to 0.96; p
Figure 2 Incidence of Atrial Fibrillation or Flutter
New onset of atrial fibrillation or flutter in patients without atrial
fibrillation or flutter at baseline. CI  confidence interval; HR  hazard ratio.
 End Point                                             With Baseline       No
                                                                          AF/F              P
HF Hospitalization / CV Death                             No               
                                                                              Yes              
All-Cause Mortality                                              No               
CV Mortality                                                         No               
All-Cause Hospitalization                                     No               
HF Hospitalization                                                No               
All-Cause Death or All-Cause Hospitalization     No               
HF Death or HF Hospitalization                           No               
CV Hospitalization                                                No               
Fatal / Non-Fatal MI                                             No               
Hospitalization for Worsening Renal Function    No                
Hospitalization for Hyperkalemia                         No               
Figure 3 Effects of Eplerenone by Baseline Atrial Fibrillation or
Effects of eplerenone on major endpoints with interaction according to the presen
AF/F  atrial fibrillation/flutter; CI  confidence interval; CV  cardiovascular; HF0.034). An adjusted analysis with covariables reduced the
magnitude of the effect slightly (HR: 0.713, 95% CI: 0.485
to 1.050; p  0.087).
Analysis of adverse event reports gave a similar finding
with 55 and 76 cases reported for the eplerenone and
placebo groups, respectively. Background use of ACE in-
hibitor or ARB did not influence the results (data not
shown).
The effect of eplerenone on the primary endpoint (car-
diovascular mortality or hospitalization for HF) was similar
among patients with and without AFF at baseline (HR:
0.60, 95% CI: 0.46 to 0.79 vs. HR: 0.70, 95% CI: 0.57 to
0.85, respectively; p for interaction  0.411) (Fig. 3). There
were also similar effects of eplerenone on other major
endpoints with no interaction according to the presence or
absence of AFF at baseline. When adjusting for background
use of an ACE inhibitor or an ARB at baseline, there was
no significant interaction with the findings and treatment
effect was maintained (data not shown).
The risk of the primary and secondary mortality and
morbidity endpoints according to baseline AFF status (for
both treatment groups combined) was not significantly
higher in subjects with and without baseline AFF (HR:
1.13, 95% CI: 0.96 to 1.33; p  0.152). For other major
adjudicated cardiovascular endpoints, the findings were
        Hazard Ratio (95% CI)                  P-value for 
                                                                       Interaction 
                                                                            0.411 
                                                                            0.453 
                                                                            0.699 
                                                                            0.223 
                                                                            0.485 
                                                                            0.260 
                                                                            0.491 
                                                                            0.204 
                                                                           0.758 
                                                                          0.927 
                                                                             N/A 
0.1 0.2 0.5 1 2 5 10
Eplerenone         Placebo
           Better                 Better 
er
bsence of atrial fibrillation or flutter at baseline.
rt failure; MI  myocardial infarction.. of       
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Eplerenone and AF in Mild Systolic Heart Failure May 1, 2012:1598–603similar between these groups except for all-cause hospital-
ization, which was associated with increased risk by AFF
(HR: 1.17, 95% CI: 1.03 to 1.34) as well as all-cause death
or all-cause hospitalization (HR: 1.18, 95% CI: 1.05 to
1.34). Adjusted analyses with covariables as in Table 2
showed similar results.
Discussion
In patients with systolic HF and mild symptoms, addition
of eplerenone to recommended therapy reduced the inci-
dence of new atrial fibrillation by 42%. Furthermore, the
benefits of eplerenone in patients with a history of atrial
fibrillation, or current atrial fibrillation, at baseline were
similar to those in patients without atrial fibrillation. These
benefits were obtained even though nearly all patients were
also treated with other effective and recommended pharma-
cological agents (i.e., ACE inhibitors/ARBs and beta-
blockers). Atrial fibrillation is a common arrhythmia in
patients with HF and is related to the severity of HF. The
annual incidence of atrial fibrillation in this trial was around
3%, which corresponds to an annual incidence of 4% to 5%
in the COMET (Carvedilol Or Metoprolol European Trial)
study (18) and the SHIFT (Systolic Heart failure treatment
with the If inhibitor ivabradine Trial) study (19) as more
ymptomatic patients in New York Heart Association
unctional class III were included in the latter 2 trials. The
rognostic importance of atrial fibrillation per se is unclear,
nd in the present analysis we could not find an independent
rognostic risk for cardiovascular events or death by AFF
ver and above other risk factors in HF. This observation is
n agreement with the recent meta-analysis by Wasywich et
l. (20).
Whether or not atrial fibrillation is an independent
redictor of outcome in HF, its occurrence is commonly
ssociated with symptom deterioration, and in addition
trial fibrillation increases the risk of stroke (21), necessi-
ating treatment with anticoagulation with its associated
nconvenience, cost, and bleeding hazard. Consequently,
trial fibrillation is best avoided, if possible. Unfortunately,
here are few treatment options for preventing atrial fibril-
ation in HF. Although retrospective analyses and small
rospective studies have suggested that ARBs (and ACE
nhibitors) might prevent atrial fibrillation (8), this finding
as not been confirmed in large prospective trials (10,11)
nd, in any case, atrial fibrillation still occurs frequently in
atients taking these drugs, as shown in the present study.
eta-blockers may also reduce the incidence of AFF but
hould, in any case, be used routinely in systolic HF. (22).
eta-blockers were used extensively in EMPHASIS-HF
nd despite this (and the use of ACE inhibitors and ARBs),
plerenone still reduced the incidence of AFF. Additional
revention can be achieved by class III antiarrhythmic
rugs, which have been shown to reduce the incidence of
trial fibrillation in HF (23), but these agents have unac-
eptable toxicity and uncertain safety in patients with acutend severe HF (23,24). By comparison, eplerenone is a
ell-tolerated and safe alternative that has substantial ad-
itional clinical benefits, provided it is initiated under
onitoring of serum potassium and creatinine as in our
tudy.
The mechanism, or mechanisms, through which epler-
none reduced the incidence of atrial fibrillation is uncer-
ain. Renin-angiotensin-aldosterone system activation may
ontribute to atrial remodeling and fibrosis in HF, which are
hought to be key triggers of atrial fibrillation. MRAs
ttenuate structural remodeling of the atria in animal
odels and improve electrical remodeling, at least in part by
educing fibrosis in animal models (7,25,26). MRAs may
lso reduce cardiac electrical instability by reducing the risk
f hypokalemia.
tudy limitations. Our results may not be applicable to all
atients with mild symptoms, because in this study patients
ere required to have additional factors known to increase
ardiovascular risk, including age 55 years, in most cases
n ejection fraction 30%, and a recent cardiovascular
ospitalization. Although the incidence of new atrial fibril-
ation was collected prospectively using a specific investigator-
ompleted CRF, we did not carry out ambulatory monitor-
ng. Consequently, we are likely to have underestimated the
ncidence of atrial fibrillation, particularly paroxysmal atrial
brillation, unless such episodes resulted in deterioration in
ymptoms necessitating physician contact or admission to
ospital. Our sensitivity analysis based on adverse event
eporting suggests that our findings are robust, but the
agnitude of underreporting remains uncertain.
onclusions
n patients with systolic HF and mild symptoms, addition
f eplerenone to recommended therapy reduced the inci-
ence of new onset AFF. The effects of eplerenone on the
isk of major cardiovascular events were similar in patients
ith and without AFF at baseline.
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